ak 2123 has been researched along with Metastase in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konovalova, NP | 1 |
| Kagiya, TV; Konovalova, NP; Kotelnikova, RA; Tatyanenko, LV; Volkova, LM; Yakushchenko, TN | 1 |
2 other study(ies) available for ak 2123 and Metastase
| Article | Year |
|---|---|
Ultralow doses of various drugs in chemotherapy of experimental tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Indazoles; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Mitomycin; Neoplasm Metastasis; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Inhibitory effect of radiosensitizer AK-2123 on experimental hepatic metastases and Ca2+ active transport.
Topics: Adenocarcinoma; Animals; Biological Transport, Active; Ca(2+) Mg(2+)-ATPase; Calcium; Colonic Neoplasms; Female; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Radiation-Sensitizing Agents; Triazoles | 1997 |